Amferia Recognized on Ny Teknik’s Prestigious “33-listan” for Second Consecutive Year
The significance of being on the list a second time highlights Amferia's continued growth and increasing market potential. It suggests that the company has not only managed to sustain its initial success but has also demonstrated the ability to expand and strengthen its position within the industry. Being recognized again reflects a track record of strong performance, innovation, or strategic decisions that make Amferia a promising company for future growth.
Amferia has once again earned a spot on Ny Teknik’s esteemed “33-listan,” an annual list of 33 promising young Swedish companies with the potential to become high-growth leaders in their industries. This recognition, awarded following a rigorous evaluation by a panel of experts, highlights Amferia's innovation, scalable business model, and high-growth potential on both Swedish and global markets.
Amferia is tackling one of the healthcare sector’s most pressing issues: infections worsened by antibiotic resistance. The company's breakthrough antimicrobial material, developed through extensive research at Chalmers University of Technology, leverages protective peptide-hydrogels to create a safe and sustainable solution to bacterial infections in both human and veterinary applications. The material’s unique structure traps and neutralizes bacteria—including antibiotic-resistant strains—almost instantly upon contact.
Amferia’s first product, an advanced wound dressing for animals, is available in nine European countries, including eight markets through a partnership with Orkla Wound Care. The company’s upcoming goals include expanding into human healthcare, with a second clinical study set to launch in Europe next year and U.S. FDA approval anticipated by mid-2025.
“Being recognized a second-time by Ny Teknik’s 33-listan is a significant milestone for Amferia, underscoring our progress in bringing a critical, technology-driven healthcare innovation to market,” stated the Amferia team. “This achievement is also a testament to the collaboration and support from our clinical partners who have recognized the vital role our technology can play in addressing a global healthcare threat.”
Ny Teknik has been recognizing Sweden’s most innovative and promising tech companies through its “33-listan” since 2008.
Read the full coverage from Ny Teknik
For additional information contact:
Anand Rajasekharan, CEO and co-founder of Amferia
+46 76 298 12 38
anandk@amferia.com
Amferia's antimicrobial amphiphilic hydrogel kills bacteria, even resistant bacteria without harming the body. The material was developed through several years of research in collaboration with Chalmers University of Technology and. Amferia's innovative, anti-microbial solution can be used on wide-ranging wounds from simple skin injuries to post-operative wounds, chronic wounds, and trauma and burn wounds. The first product from this technology platform is a wound-care dressing for dry-to-low exuding wounds. Amferia has ongoing clinical investigations in Europe and is seeking CE marking and FDA clearance for human application.
Read more about the products, team, technology and publications at www.amferia.com
